Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

BACKGROUND: A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with a significant improvement in progression-free surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Robert, Mathews, Lindsay, Liu, Mitchell, Schellenberg, Devin, Mou, Benjamin, Berrang, Tanya, Harrow, Stephen, Correa, Rohann J. M., Bhat, Vasudeva, Pai, Howard, Mohamed, Islam, Miller, Stacy, Schneiders, Famke, Laba, Joanna, Wilke, Derek, Senthi, Sashendra, Louie, Alexander V., Swaminath, Anand, Chalmers, Anthony, Gaede, Stewart, Warner, Andrew, de Gruijl, Tanja D., Allan, Alison, Palma, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201684/
https://www.ncbi.nlm.nih.gov/pubmed/32370765
http://dx.doi.org/10.1186/s12885-020-06876-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201684/
https://www.ncbi.nlm.nih.gov/pubmed/32370765
http://dx.doi.org/10.1186/s12885-020-06876-4

Ejemplares similares